OSE Immunotherapeutics gets first patient dosed in RENGEVITY-201
OSE Immunotherapeutics said its licensee Veloxis Pharmaceuticals announced the first patient has been dosed in RENGEVITY-201, a Phase 2 trial evaluating pegrizeprument (VEL-101) for kidney transplant rejection prevention.